Orrin Hatch

Context: Hatch introduced the Ensuring Patient Access and Effective Drug Enforcement Act, narrowing the broad authority of the DEA to suspend drug "manufacturers, distributors, and dispensers". Hatch stated the bill was also written to protect patients from disruptions in the production and delivery of their prescription drugs: "The fact that prescription drugs can be abused should not prevent patients from receiving the medications they need. This bill takes a balanced approach to the problem of prescription drug abuse by clarifying penalties for manufacturing or dispensing outside approved procedures while helping to ensure that supply chains to legitimate users remain intact". The bill passed the Senate unanimously and Tom Marino passed a version of the bill in the House and was signed by President Barack Obama.  Critics of the bill claim the new law fuels the opioid crisis by limiting the DEA's ability to halt production and distribution by predatory drug companies. DEA Chief Administrative Law Judge John J. Mulrooney II wrote in the Marquette Law Review: "At a time when, by all accounts, opioid abuse, addiction and deaths were increasing markedly, this new law imposed a dramatic diminution of the agency's authority. It is now all but logically impossible for the DEA to suspend a drug company's operations for failing to comply with federal law." Donald Trump's Attorney General Jeff Sessions called the law "dubious" and joined 44 state attorneys general calling for "repeal or amendment of the law to restore some of the DEA's authority." Jim Geldhof, a former DEA program manager whom spent 43 years with the DEA called the bill "outrageous. It basically takes any kind of action DEA was going to do with a distributor or manufacturer as far as an immediate suspension off the table. And then the other part of that really infuriates me is that corrective action plan." Mulrooney compared the corrective action plan to one that would "allow bank robbers to round up and return inkstained money and agree not to rob any more banks -- all before any of those wrongdoers actually admit fault and without any consequence that might deter such behavior in the future."  Hatch responded to a Washington Post and 60 Minutes investigation into the bill by writing a Washington Post opinion article calling the investigation "misleading" and asking to "leave conspiracy theories to Netflix". Senator Sheldon Whitehouse, a co-sponsor of the senate bill, also defended the bill: "This bill was drafted in consultation with the DEA to offer better guidance for companies working to safely and responsibly supply prescription drugs to pharmacies, and to promote better communication and certainty between companies and regulators."  Republican Pat Toomey Pat Toomey expressed doubts that a conspiracy existed, but still suggested amending the bill: "I'm a little surprised that it passed unanimously in both houses, was signed by President Obama and got no opposition from the DEA at the time. That's not the way controversial legislation usually ends up, but hey, if there's problems, then we ought to revisit them."  Hatch received $177,000 in donations from the drug industry while pushing the bill through and has received $2,178,863 from the Pharmaceuticals/Health Products industry from 1989-2014 according to required filings by the Federal Election Commission. CANNOTANSWER

Question: Are there any other interesting aspects besides opioid crisis about this article?
Answer: Hatch introduced the Ensuring Patient Access and Effective Drug Enforcement Act,